BioLargo, Inc. (OTCQX:BLGO), a cleantech innovator that creates and commercializes sustainable technologies, today announced that it has revoked the technology license granted to Pooph Inc. ("Pooph") and was terminating the license agreement after Pooph "failed to meet its contractual obligations," including payments owed to BioLargo totaling approximately $3.8 million.
BioLargo's formal notice advised that Pooph is no longer allowed to market or sell products that incorporate, use, or are based on, in whole or in part, BioLargo's patents and proprietary information, including but not limited to know-how, disclosed to Pooph, and that absent reinstatement of the grant of license, Pooph must immediately stop marketing and selling any such products in its possession, custody or control (or sold through market portals or platforms such as Amazon), BioLargo CEO Dennis Calvert announced today.
Pooph's emergence as a nationally recognized consumer brand was made possible by BioLargo's products, technical and commercial know-how, extensive market experience, and the collaborative business relationship between the parties. Powered by BioLargo's proprietary technology, Pooph products reached more than $50 million in annual sales and earned tens of thousands of positive customer reviews.
“We remain fully committed to advancing our broad portfolio of technologies, products, and services,” Calvert says. “Our commercial efforts continue to focus on delivering transformative solutions in infection control and wound care, breakthrough technologies for managing 'forever chemicals,' and innovative battery systems. We remain steadfast in protecting our intellectual property and expanding the reach of our proven odor-control technology into new markets-providing consumers with safe, effective, and environmentally friendly products.
"Our science," he adds, "has been validated in the marketplace at scale. While we regret the outcome of this relationship, we remain confident in the strength of our technology and the significant opportunities ahead. Our duty is to our stockholders, our partners, and the integrity of our work-and we will continue to build on this proven success."
BioLargo filed a Form 8-K with the U.S. Securities and Exchange Commission on September 25, 2025 (https://www.biolargo.com/sec-filings).
BioLargo’s core products address PFAS contamination, achieve advanced water and wastewater treatment, control odor and VOCs, improve air quality, enable energy-efficiency and safe on-site energy storage, and control infections and infectious disease.
“Our approach,” Calvert says, “is to invent or acquire novel technologies, develop them into product offerings, and extend their commercial reach through licensing and channel partnerships to maximize their impact.”
For more, go to www.BioLargo.com.
Copyright © 2025 California Business Journal. All Rights Reserved.
For California Business Journal Disclaimers, go to /terms-conditions/.
